PT  - JOURNAL ARTICLE
AU  - S. Yeasmin
AU  - K. Nakayama
AU  - M. Ishibashi
AU  - A. Oride
AU  - A. Katagiri
AU  - I. N. Purwana
AU  - K. Iida
AU  - N. Nakayama
AU  - H Ishikura
AU  - K. Miyazaki
TI  - Therapy-related myelodysplasia and acute myeloid leukemia following paclitaxel- and carboplatin-based chemotherapy in an ovarian cancer patient: a case report and literature review
AID  - 10.1111/j.1525-1438.2007.01185.x
DP  - 2008 Oct 01
TA  - International Journal of Gynecologic Cancer
PG  - 1371--1376
VI  - 18
IP  - 6
4099  - http://ijgc.bmj.com/content/18/6/1371.short
4100  - http://ijgc.bmj.com/content/18/6/1371.full
SO  - Int J Gynecol Cancer2008 Oct 01; 18
AB  - Alkylating agents have strong leukemogenic potential. There are a number of recent acute myeloid leukemia (t-AML) cases related to previous paclitaxel exposure. These leukemias tend to be of aggressive subtypes with long-latency periods. Unlike previously reported cases, the present case was of the secondary acute megakaryoblastic myeloid leukemia (AML M7) subtype. Additionally, it did not harbor a translocation in chromosome 19. A 73-year-old woman was diagnosed with t-AML M7 with antecedent myelodysplasia. Leukemia followed a second induction of paclitaxel- and carboplatin-based chemotherapy for recurrent ovarian cancer. Her second induction began 25 months after completion of her first course of chemotherapy. The increased incidence of postpaclitaxel leukemia suggests a probable role for paclitaxel as a leukemogenic agent. It highlights the importance of assessing for leukemia risk factors prior to beginning paclitaxel therapy.